关键词: 乳腺癌, 拓扑异构酶Ⅱ, P53, 新辅助化疗

Abstract: 【Abstract】 Objective〓To investigate whether the expression of TOPOⅡ and P53 expression in breast cancer could predict the efficacy of neoadjuvant chemotherapy. Methods〓This research retrospectively analyzed 185 patients, who were diagnosed as invasive ductal carcinomas in stage Ⅱ-Ⅲ, admitted in the Breast Cancer Center in our hospital and accepted NAC from October 2011 to August 2015. Immunohistochemical assay was used to detect the TOPOⅡ and P53 protein levels of 185 breast cancer tissues obtained by core needle biopsy before neoadjuvant chemotherapy. The relationship of TOPOⅡ and P53 expression with clinicopathological characteristics as well as prognosis of neoadjuvant chemotherapy was statistically analyzed. Results〓The objective response rate (ORR) of patients with positive TOPOⅡ expression was significantly higher than that of patients with negative TOPOⅡ expression. The clinical complete response (cCR ) proportion of patients with positive P53 expression was larger than that of patients with negative P53 expression. The patients with both positive TOPOⅡ and P53 expression not only achieved a higher rate of ORR but had a larger proportion of cCR than the case in patients not with both positive TOPOⅡ and P53 expression. Conclusion〓The protein levels of TOPOⅡ and P53 showed predictive value of the efficacy of neoadjuvant chemotherapy based on anthracyclines.

Key words: Breast cancer, TOPOⅡ, P53, Neoadjuvant chemotherapy